MedTrace Logo

Sodium Channel Splicing in Heart Failure Trial

NCT01185587 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 147

Last updated 2014-04-23

No results posted yet for this study

Summary

The purpose of this research is to see if investigators can detect truncated mRNA splice variants of the cardiac voltage-gated sodium (Na+) channel gene, SCN5A, in patients with a weak heart (Heart Failure) with or without an implantable cardioverter-defibrillator (ICD) and compare them to patients with a normal heart.

Hypothesis:

1. Patients with reduced left ventricular ejection fraction have increased abundances truncated mRNA splice variants of the SCN5A gene, which portends to sodium channel dysfunction and an increased risk for sudden cardiac death.
2. Patients with implantable cardioverter-defibrillator devices (ICDs) who have experienced shock therapy have increased abundances of truncated mRNA splice variants of the SCN5A gene compared to similar congestive heart failure patients who have not experienced shock therapy.

Conditions

Sponsors & Collaborators

  • Jesse Brown VA Medical Center

    collaborator FED

  • University of Illinois at Chicago

    lead OTHER

Principal Investigators

  • Samuel C. Dudley, Jr., MD, PhD · University of Illinois at Chicago

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01185587 on ClinicalTrials.gov